Evofem Biosciences reports Q2 results

Aug. 04, 2022 4:37 PM ETEvofem Biosciences, Inc. (EVFM)By: Niloofer Shaikh, SA News Editor
  • Evofem Biosciences press release (NASDAQ:EVFM): Q2 loss from operations improved 16% to $24.4M.
  • Revenue of $6M (+215.8% Y/Y) misses by $0.05M.
  • Evofem (EVFM) continues to expect net product sales in the range of $30M to $35M for its 2022 fiscal year, representing 264% to 325% growth year-over-year vs. consensus of $31.34M. Gross-to-net is expected to be 40% or better, trending toward the lower in the second half of the year. The company remains on track to meet its goal of reducing costs by $50M in 2022; total operating expenses were $25.3M lower in the first half of 2022 versus the same period last year.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.